Article

Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms

Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Japan.
Arthritis & Rheumatology (Impact Factor: 7.87). 10/2009; 61(10):1305-11. DOI: 10.1002/art.24460
Source: PubMed

ABSTRACT To assess L-tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT-associated eosinophilia-myalgia syndrome (EMS) and related clinical findings.
HLA-DRB1 and DQA1 allele typing and Gm/Km phenotyping were performed on a cohort of 94 white subjects with documented LT ingestion and standardized evaluations. Multivariate analyses compared LT dose, age, sex, and alleles among groups of subjects who ingested LT and subsequently developed surveillance criteria for EMS, developed EMS or characteristic features of EMS (EMS spectrum disorder), or developed no features of EMS (unaffected).
Considering all sources of LT, higher LT dose (odds ratio [OR] 1.4, 95% confidence interval [95% CI] 1.1-1.8), age >45 years (OR 3.0, 95% CI 1.0-8.8), and HLA-DRB1*03 (OR 3.9, 95% CI 1.2-15.2), DRB1*04 (OR 3.9, 95% CI 1.1-16.4), and DQA1*0601 (OR 13.7, 95% CI 1.3-1.8) were risk factors for the development of EMS, whereas DRB1*07 (OR 0.12, 95% CI 0.02-0.48) and DQA1*0501 (OR 0.23, 95% CI 0.05-0.85) were protective. Similar risk and protective factors were seen for developing EMS following ingestion of implicated LT, except that DRB1*03 was not a risk factor and DQA1*0201 was an additional protective factor. EMS spectrum disorder also showed similar findings, but with DRB1*04 being a risk factor and DRB1*07 and DQA1*0201 being protective. There were no differences in sex distribution, Gm/Km allotypes, or Gm/Km phenotypes among any groups.
In addition to the xenobiotic dose and subject age, polymorphisms in immune response genes may underlie the development of certain xenobiotic-induced immune-mediated disorders, and these findings may have implications for future related epidemics.

Download full-text

Full-text

Available from: Rossanne M Philen, Jul 30, 2015
0 Followers
 · 
84 Views
  • Source
    • "Multiple variables should be studied and combined in novel ways to develop criteria that can distinguish with high sensitivity and specificity individuals likely to develop disease after a given exposure Higher dose and older age were risk factors for development of eosinophilia myalgia syndrome after L-tryptophan [36] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence supports a role for the environment in the development of autoimmune diseases, as reviewed in the accompanying three papers from the National Institute of Environmental Health Sciences Expert Panel Workshop. An important unresolved issue, however, is the development of criteria for identifying autoimmune disease phenotypes for which the environment plays a causative role, herein referred to as environmentally associated autoimmune diseases. There are several different areas in which such criteria need to be developed, including: 1) identifying the necessary and sufficient data to define environmental risk factors for autoimmune diseases meeting current classification criteria; 2) establishing the existence of and criteria for new environmentally associated autoimmune disorders that do not meet current disease classification criteria; and 3) identifying in clinical practice specific environmental agents that induce autoimmune disease in individual patients. Here we discuss approaches that could be useful for developing criteria in these three areas, as well as factors that should be considered in evaluating the evidence for criteria that can distinguish individuals with such disorders from individuals without such disorders with high sensitivity and specificity. Current studies suggest that multiple lines of complementary evidence will be important and that in many cases there will be clinical, serologic, genetic, epigenetic, and/or other laboratory features that could be incorporated as criteria for environmentally associated autoimmune diseases to improve diagnosis and treatment and possibly allow for preventative strategies in the future.
    Journal of Autoimmunity 07/2012; 39(4). DOI:10.1016/j.jaut.2012.05.001 · 7.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aromatic amino acids (AAA) are very important amino acids in the body and have been suggested to be involved in many diseases. We describe the development and full validation of a high performance liquid chromatography with fluorescence detection (HPLC-FLD) method for simultaneously quantitative determination of serum AAA. Furthermore, we aimed to explore the clinical significances of AAA for chronic kidney disease (CKD). Serum samples were deproteinized by perchloric acid. Separation was carried out on a Megres C18 column (4.6 mm×250 mm i.d., 5 μm). The mobile phase consisted of 10% acetonitrile (v/v) in water and was run at a flow rate of 1.0 ml/min. The eluted AAA was monitored by measuring the fluorescence intensity using the programmed wavelength detection setting. AAA determination in a serum sample was achieved in <10 min. The linear ranges of the method were 0.55-275 μmol/l, 3.05-1220.0 μmol/l and 0.049-49 μmol/l for Tyr, Phe and Trp, respectively. The limit of detection (LOD) was 0.014 μmol/l for Tyr, 0.5 μmol/l for Phe, and 0.0049 μmol/l for Trp. Recovery and reproducibility were satisfactory. Compared with healthy control subjects, the CKD patients showed lower serum levels of AAA. It should probably available to apply for screening and monitoring of CKD. The method is simple, fast, accurate, and suitable for routine analysis.
    Clinica chimica acta; international journal of clinical chemistry 02/2011; 412(11-12):1032-5. DOI:10.1016/j.cca.2011.02.015 · 2.76 Impact Factor
  • Endocrinología y Nutrición 06/2011; 58(6):319-320. DOI:10.1016/j.endonu.2010.12.007
Show more